Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended			6 Months Ended		3 Months Ended		6 Months Ended				3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jul. 30, 2014 Subsequent Event [Member] SWK Funding LLC [Member]	Jun. 30, 2014 Subsequent Event [Member] SWK Funding LLC [Member]	Jun. 30, 2014 Maximum [Member] Purchased And Internally Developed Software Intangible Asset [Member]	Jun. 30, 2014 Minimum [Member] Purchased And Internally Developed Software Intangible Asset [Member]	Jun. 30, 2014 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Jun. 30, 2013 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Jun. 30, 2014 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Jun. 30, 2013 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Jun. 30, 2014 Clinical [Member]	Dec. 31, 2013 Clinical [Member]	Jun. 30, 2014 ResponseDX [Member]	Jun. 30, 2013 ResponseDX [Member]	Jun. 30, 2014 ResponseDX [Member]	Jun. 30, 2013 ResponseDX [Member]	Dec. 31, 2013 ResponseDX [Member]
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts	$ 6,529,550		$ 6,529,550		$ 6,225,923									$ 1,060,649	$ 1,892,384
Allowance for doubtful accounts	1,912,668		1,912,668		2,404,659											1,912,668		1,912,668		2,404,659
Revenue from pharmaceutical clients	599,282	2,207,837	1,176,663	4,649,531
Bad debt expense			2,661,693	818,451												1,367,842	349,984	2,661,693	818,451
Line of credit, expiration date			Jul. 25, 2016		Mar. 07, 2015
Line of credit, fee for unused portion			0.25%
Line of credit, borrowing base percentage of pharmaceutical accounts receivable	80.00%		80.00%
Line of credit, interest above prime rate			1.00%
Line of credit, interest charged	5.00%	5.00%	5.00%	5.00%
Line of credit, amount drawn	1,500,000		1,500,000		1,000,000
Advertising costs	19,839	3,324	26,260	3,324
Uninsured foreign cash balance	12,719		12,719
Concentration risk percentage										71.00%	93.00%	72.00%	92.00%
Payment period from the date of invoice														45 days
Line of Credit Facility,Agreement Date			Jul. 14, 2011
Cash and cash equivalents that exceeded federally insured limits	2,124,809		2,124,809
Finite-Lived Intangible Asset, Useful Life								5 years	3 years
Payments for Fees			40,000
Mortgage Loans on Real Estate, Final Maturity Date			Jul. 25, 2016
Line Of Credit Facility Fees Payable						$ 10,000	$ 10,000
Loans Receivable, Description of Variable Rate Basis			2.25%